Episode 96

Precision Medicine and Clonal Hematopoiesis

Join us on this podcast episode featuring Prof Helen Papadaki (University of Crete, Greece) as she discusses the link between clonal hematopoiesis and the risk of developing MDS or AML.

Prof. Papadaki begins by explaining the difference between CHIP (clonal hematopoiesis of indeterminate potential), CCUS (clonal cytopenia of undetermined significance) and ICUS (Idiopathic cytopenia of undetermined significance). She underlines the clinical relevance of the association of clonal hematopoiesis with cytopenias, as a clear indicator of an increased risk of developing hematological malignancies.

Learn how important it is to better characterize by NGS sequencing the specific mutations of the clones, given that the type of mutation, the number of mutations, and the combination of mutations are critical parameters in accurately predicting the risk of developing MDS or AML.

Furthermore, Prof Papadaki explains the importance of discriminating between acquired and germline mutations leading to clonal hematopoiesis and their relationship with age. Finally, she highlights the fact that clonal hematopoiesis is a risk factor for developing not only hematological malignancies but also cardiac diseases.

Host: Isabel Olivera-Martinez, PhD

Guest: Prof Helen Papadaki

This is the third episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!